Alzheimer's disease drug development pipeline: 2020

Abstract

Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD. We use the Common Alzheimer's and Related Dementias Research Ontology (CADRO) to classify treatment targets and mechanisms of action. We review our annual pipeline reports for the past 5 years to provide longitudinal insight into clinical trials and drug development for AD. Methods We reviewed ClinicalTrials.gov as of February 27, 2020, and identified all trials of pharmacologic agents currently being developed for treatment of AD as represented on this widely used U.S. Food and Drug Administration registry. Results There are 121 agents in clinical trials for the treatment of AD. Twenty‐nine agents are in 36 Phase 3 trials, 65 agents are in 73 Phase 2 trials, and 27 agents are in 27 Phase 1 trials. Twelve agents in trials target cognitive enhancement and 12 are intended to treat neuropsychiatric and behavioral symptoms. There are 97 agents in disease modification trials. Compared to the 2019 pipeline, there is an increase in the number of disease‐modifying agents targeting pathways other than amyloid or tau. Discussion The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. Review of clinical trials over the past 5 years show that there is progressive emphasis on non‐amyloid targets, including candidate treatments for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions. There has been a marked growth in repurposed agents in the pipeline.

Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer

“…The fact that breast cancer is the second most common cancer in women (after skin cancer) and that women are disproportionately affected by AD and related dementia provides us with an opportunity to reduce the global disease burden of NDDs. 58…”

Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease

“…Cognitive ability is quickly reduced as tau pathology spreads through the brain, making tau an attractive candidate for slowing the disease progression. 64,65 For targeting tau, there are additional considerations regarding the variety of splicing isoforms, truncations, and posttranslational modifications naturally occurring in the brain. A single patient may have a heterogeneous population of pathogenic tau "seeds."…”

A Report From the 8th Kuopio Alzheimer Symposium

“…In 2018, 112 drugs are in the development pipeline for AD. Of these, 23 agents (in 25 trials) are in phase I, 63 agents (in 75 clinical trials) in phase II, and 26 agents (in 35 trials) in phase III [4].…”

“…Sixty three percent are disease-modifying drugs, 22 % are symptomatic cognitive enhancers and 12 % address neuropsychiatric or behavioral symptoms [4]. Despite the large number of trials, many initially promising clinical trials have been discontinued because of the lack of efficacy or adverse side effects over the last decades.…”